

Date of Deposit is MAY 17, 2000

I hereby certify that this is being deposited with the United States Postal Service under 37 CFR 1.8 on the date indicated above and is addressed to the Assistant Commissioner for Patents, Box: SEQUENCE

By:

Lois E. Miller

PATENT/DX0903K

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

J. Fernando BAZAN

Serial No.: 09/399,492

Filed: 20-SEP-1999

For: MAMMALIAN CYTOKINES;
RELATED REAGENTS

Examiner: G. Draper

Art Unit: 1646

SUBSTITUTE SEQUENCE SUBMISSION

Palo Alto, California 94304-1104

MAY 17, 2000

RECEIVED

MAY 25 2000

TECH CENTER 1600/2900

Assistant Commissioner for Patents
Box: SEQUENCE
Washington, D.C. 20231

Sir:

**COMPLIANCE WITH REQUIREMENTS FOR PATENT APPLICATIONS
CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE
DISCLOSURES**

In response to receipt of a "Notice to Comply with Requirements for Patent Applications containing Nucleotide and/or Amino Acid Sequences," dated 17-APR-00 (Paper No. 7) for the above-identified application, Applicants submit: (1) a substitute paper and write-protected computer readable copy of the Sequence Listing as required under 37 CFR §1.825(d); (2) a statement under 37 CFR §1.825(d) and (3) a copy of the "Error Report."

Remarks

The enclosed sequence submission corrects the previous sequence submission by applying a PATENTIN 2.0 feature format (i.e., numeric identifiers <220-223>) to the use of "n" or "Xaa" in the listing. To the best of Applicant's knowledge and belief, the informational content of the sequence itself remains unchanged, only the file presentation format has been changed. For example, in SEQ ID NO: 2 the Xaa in the polypeptide sequence at residue 61 was identified using the feature format.

The enclosed submission is a substitute write protected floppy diskette containing the "Sequence Listing." The diskette complies with the requirements of 37 CFR §1.824 and is IBM PC compatible with a PC-DOS/MS-DOS operating system. If the diskette is damaged, please contact Applicant's representative and a replacement diskette will be provided. A paper readable copy of the substitute Sequence Listing on the diskette is attached hereto.

The informational content of the substitute paper and substitute computer readable copies of the sequence listing, submitted in accordance with 37 CFR §1.825(d) are believed to be the same and are believed to include no new matter since the informational content of the enclosed sequences should be the same as the informational content of the sequences submitted in priority documents.

The enclosed items are a bona fide effort to bring the present application into full compliance with the rules for sequence submissions. Applicants have invested over three hours of significant additional labor and care in preparing the present submission. Should there be any question regarding the sufficiency of this submission to comply with the rules for sequence submissions, Applicant respectfully requests notification of specific deficiencies and an opportunity for remedy, under 37 CFR §1.135(c).

Applicants believe no fees are due, however, if any fees are required, the Commissioner is authorized to make any appropriate charges or credit any overpayment to DNAX Research Institute Deposit Account No. 04-1239.

Respectfully submitted,

Dated: MAY 17, 2000

By: 

Gerald P. Keleher
Reg. No. 43,707

Enclosures and attachments:

One substitute write-protected diskette (CRM); and
Substitute paper copy of contents of diskette.

DNAX Research Institute
901 California Avenue
Palo Alto, California 94304-1104
TEL: (650) 852-9196
FAX: (650) 496-1200